Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 5/20 | 0.60 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3845576 | 0.85 | ADORA2A (0.45) | CLK1TGFBR1ADORA2AEPHB3 | |
| SCHEMBL4250692 | 0.84 | ADORA2A (0.47) | CLK1TGFBR1ADORA2AEPHB3 | |
| SCHEMBL14145741 | 0.83 | CLK1 (0.61) | CLK1TGFBR1EPHB3 | |
| SCHEMBL1614377 | 0.83 | ADORA2A (0.47) | CLK1TGFBR1ADORA2AEPHB3PIK3CA | |
| SCHEMBL15639434 | 0.82 | PIK3CA (0.45) | CLK1TGFBR1ADORA2AEPHB3PIK3CA | |
| SCHEMBL1649588 | 0.81 | TGFBR1 (0.47) | CLK1TGFBR1ADORA2AEPHB3PIK3CA | |
| SCHEMBL21085001 | 0.80 | TGFBR1 (0.54) | CLK1TGFBR1ADORA2AEPHB3 | |
| SCHEMBL21084989 | 0.80 | TGFBR1 (0.51) | TGFBR1 | |
| SCHEMBL12850103 | 0.80 | ADORA2A (0.45) | CLK1TGFBR1ADORA2AEPHB3PIK3CA | |
| SCHEMBL22940951 | 0.79 | CLK1 (0.57) | CLK1TGFBR1EPHB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137469-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250206746-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-06-26 | — | — | US | disclosed |
| CN-119604506-A | 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof | 拜斯丽治疗有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023250156-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | CLK1 175/4885TGFBR1 1554/4885ADORA2A 329/4885 |
| US-20250206746-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | CLK1 175/4885TGFBR1 1554/4885ADORA2A 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.